2021
ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman K, Sikov W, Carey L, Hwang E, Poppe M, Partridge A, Ollila D, Golshan M. ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 436-437. DOI: 10.1245/s10434-021-10005-1.Peer-Reviewed Original ResearchFactors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 5960-5971. PMID: 33821344, PMCID: PMC8532250, DOI: 10.1245/s10434-021-09897-w.Peer-Reviewed Original ResearchConceptsBreast pathologic complete responsePathologic complete responseResidual breast diseaseTriple-negative breast cancerNodal pathologic complete responsePretreatment nodal statusClinical nodal statusNeoadjuvant chemotherapyNodal statusAxillary surgeryComplete responseCALGB 40601YpN0 rateAxillary nodal involvementResidual nodal diseaseProportion of patientsCareful patient selectionBreast cancer patientsNAC regimensYpN0 diseaseYpN0 statusCN0 patientsNodal diseaseNodal involvementMultivariable analysis
2017
Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times.
Losk K, Freedman R, Lin N, Golshan M, Lester S, Pochebit S, Natsuhara K, Camuso K, King T, Bunnell C. Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times. Journal Of Clinical Oncology 2017, 35: 166-166. DOI: 10.1200/jco.2017.35.8_suppl.166.Peer-Reviewed Original ResearchOncotype DX testingChemotherapy initiationMedical oncologistsBreast cancerConsecutive breast cancer patientsAdjuvant chemotherapy initiationBreast cancer patientsOncotype DX resultsPathology reviewClinical outcomesTumor characteristicsMedical oncologyOncotype DXCancer patientsPatient satisfactionSurgery dateSurgical oncologyPatientsTurnaround timeSurgeryIntervention implementationMean timeOncologistsSignificant reductionOrder date
2015
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? European Journal Of Surgical Oncology 2015, 41: 1288-1292. PMID: 26238477, DOI: 10.1016/j.ejso.2015.07.013.Peer-Reviewed Original ResearchConceptsDe novo metastatic breast cancerNovo metastatic breast cancerMetastatic breast cancerBreast cancer patientsBreast cancerSurvival benefitCancer patientsPrimary tumorRetrospective non-randomized clinical studyDe novo metastatic diseasePrimary metastatic breast cancerNon-randomized clinical studyTumor-related symptomsPrimary tumor excisionSelection of patientsWound issuesBiologic therapyMetastatic diseaseSystemic therapyDistant metastasisEpidemiological burdenInitial diagnosisSurgical excisionPatient preferencesTumor excision
2014
Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction.
Golshan M, Hergrueter C, Camuso K, Lin N, Cutone L, Hirshfield-Bartek J, Roberts P, Runkle W, Kadish S, Losk K, Bunnell C. Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction. Journal Of Clinical Oncology 2014, 32: 110-110. DOI: 10.1200/jco.2014.32.30_suppl.110.Peer-Reviewed Original ResearchSurgery consultImmediate reconstructionInitial consultBreast cancer patientsPre-operative testingOptimal clinical outcomesOperating room availabilityDefinitive surgerySurgical consultClinical outcomesCancer CenterStandard referralCancer patientsPatient preferencesPatient referralPatient satisfactionCare coordinationReferral templatesSurgical oncologyBreast cancerReconstructive surgeryMastectomySurgical teamPatientsConsults
2013
Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology.
Losk K, Kadish S, Golshan M, Lin N, Hirshfield-Bartek J, Cutone L, Bunnell C, Weingart S. Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. Journal Of Clinical Oncology 2013, 31: 51-51. DOI: 10.1200/jco.2013.31.31_suppl.51.Peer-Reviewed Original ResearchInitiation of chemotherapyBreast cancer patientsMedical oncologyOncology followDefinitive surgeryCancer patientsConsecutive breast cancer patientsChemotherapy treatment delaysAdverse clinical outcomesBreast cancer careTransitions of careProcess of careAdjuvant chemotherapyTimely chemotherapyMedical oncologistsClinical outcomesTreatment delayBreast surgeryCancer careInitial consultationBreast surgeonsCare coordinationChemotherapySurgeryMultidisciplinary team
2012
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery Cortés J, Caralt M, Delaloge S, et al (Vall d'Hebron Univ Hosp, Barcelona, Spain; Institut Gustave Roussy, Villejuif Cedex, France; et al) Eur J Cancer 48:475-481, 2012§
Dominici L, Golshan M. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery Cortés J, Caralt M, Delaloge S, et al (Vall d'Hebron Univ Hosp, Barcelona, Spain; Institut Gustave Roussy, Villejuif Cedex, France; et al) Eur J Cancer 48:475-481, 2012§. Breast Diseases A Year Book Quarterly 2012, 23: 351-352. DOI: 10.1016/j.breastdis.2012.09.015.Peer-Reviewed Original ResearchMetastatic breast cancer patientsSafety of bevacizumabBreast cancer patientsCancer patientsBevacizumab
2008
Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site
Cady B, Nathan N, Michaelson J, Golshan M, Smith B. Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site. Annals Of Surgical Oncology 2008, 15: 3384-3395. PMID: 18726129, DOI: 10.1245/s10434-008-0085-x.Peer-Reviewed Original ResearchConceptsPrimary site surgeryBreast cancer patientsMatched-pair analysisIV patientsCancer resectionBreast surgeryCancer patientsSurvival advantageStage IVSite surgeryStage IV breast cancer patientsStage IV breast cancerExcellent responseApparent survival benefitBreast cancer resectionPrimary cancer resectionStage IV patientsStage III patientsSelection biasApparent survival advantageMatched pair analysisOligo metastasisInitial chemotherapyChart reviewSurvival benefitYoung Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2
Bafford A, Garber J, Chittenden A, Golshan M. Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2. Methods Of Cancer Diagnosis, Therapy And Prognosis 2008, 1: 483-491. DOI: 10.1007/978-1-4020-8369-3_33.Peer-Reviewed Original ResearchBreast cancerYoung breast cancer patientsTumor suppressor geneBreast-Conserving TherapyInvasive breast cancerBreast cancer patientsCancer-related deathSporadic breast cancerSuppressor geneClassical tumor suppressor geneCancer patientsCommon cancerCancerRole of BRCA1WomenAmerican womenBRCA2BRCA1Cell cycle regulationDNA damageMultiple cellular processesPatientsTherapyDiseaseDiagnosis
2003
The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma
Golshan M, Fung B, Wolfman J, Rademaker A, Morrow M. The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma. The American Journal Of Surgery 2003, 186: 391-396. PMID: 14553857, DOI: 10.1016/s0002-9610(03)00280-0.Peer-Reviewed Original ResearchConceptsWhole-breast ultrasonographyBreast cancer patientsSurgical managementBreast ultrasonographyCancer patientsBreast cancerHistologic grade 2Percent of patientsBreast conservation therapyHigh-grade lesionsPrimary tumor siteFoci of carcinomaUltrasonography abnormalitiesYounger patientsConservation therapyWide resectionGrade lesionsPhysical examinationAdditional lesionsSignificant abnormalitiesBreast carcinomaPatientsGrade 2UltrasonographyTumor site